ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1521

Autoantibody Microarray Signal Intensities May Predict the Occurrence of Immune-related Adverse Events
Abstract Number: 0979

Autoantibody Testing in Juvenile Localized Scleroderma and Systemic Sclerosis: Comparing Antibody Profiles and Clinical Correlations
Abstract Number: 0001

Autoantigenic Properties Indicated for the Entire Aminoacyl tRNA Synthetase Family in Idiopathic Inflammatory Myopathies
Abstract Number: 1772

Autologous EBV-specific Cytotoxic T Cells in Systemic Lupus Erythematosus: An Innovative Phase I/IIa Clinical Trial
Abstract Number: 0547

Autologous Haematopoietic Stem Cell Transplantation for Systemic Sclerosis Results in Sustained Changes in Immunoregulatory T and NK Cells
Abstract Number: 1364

Autologous Hematopoietic Stem Cell (HSC) Transplantation for Systemic Sclerosis, North American Registry: Updated Outcomes and the Impact of CD34+ HSC Enrichment
Abstract Number: 0778

Autologous Stem Cell Transplantation with CD34-Selected Peripheral Blood Stem Cells in Patients with Treatment-Resistant Juvenile-Onset Systemic Sclerosis
Abstract Number: 1474

Automatic Detection of Bone Marrow Lesions from Knee MRI Data from the OAI Study
Abstract Number: 0848

Automatic Hand Segmentation from Hand X-rays Using Minimized Training Samples and Machine Learning Models
Abstract Number: 0370

Awareness and Attitudes Regarding Axial Spondyloarthritis Among Primary Care Providers
Abstract Number: 1921

Axial Psoriatic Arthritis: Correlation Between Whole Spine MRI Abnormalities and Clinical Findings
Abstract Number: 0062

Axial Spondyloarthritis and Its Related Immune-Mediated Diseases Share a Gut Microbiome Signature Besides Their Own Distinctive Profile
Abstract Number: 1484

B Cell Intracellular IFNβ as a Unique Cellular Marker for the Development of Lupus Nephritis
Abstract Number: 1562

B Cell Reconstitution Is Strongly Associated with COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Treated with Rituximab
Abstract Number: 0982

B Cells Repertoire Repartition Predicts Response to Methotrexate at 6 and 12 Months in Naïve RA: A Machine Learning Driven Approach

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].